We are among the elite 1% NCI-designated comprehensive cancer centers in the U.S. — and we are ranked in the top 1% of all U.S. hospitals for cancer care, according to U.S. News & World Report.
Cancer Clinical Trials
- Blood & Bone Marrow Cancers
- Brain, Spine & Central Nervous System Cancers
- Breast Cancer
- Childhood Cancers
- Endocrine System Cancers
- Gastrointestinal (GI) Cancers
- Genitourinary (GU) & Urologic Cancers
- Gynecologic Cancers
- Head & Neck Cancers
- Kaposi Sarcoma & AIDS-Related Cancers
- Lung & Chest Cancers
- Prostate Cancer
- Sarcomas
- Skin Cancer
Treating More Than 200 Types of Cancer
Over 500 Active Clinical Trials
Navigating Your Cancer Care
At Montefiore Einstein Comprehensive Cancer Center, you receive evidence-based cancer care that addresses the unique needs of each individual patient. Our NCI-designated comprehensive cancer center brings the worlds of clinical care and academic research together and allows for the translation of novel, leading-edge scientific discoveries into improved clinical outcomes and new life-saving treatments.
Using a multidisciplinary team of disease-focused experts, our full-service cancer center is focused on the prevention, early diagnosis and treatment of cancer while incorporating a comprehensive spectrum of traditional and holistic care. This allows us to deliver highly specialized and coordinated compassionate care for the whole person, address complex medical needs and improve the quality of life for each and every patient.
Over 50 Years of Cancer Research & Treatment Breakthroughs
Our Latest Research
Advancing human health, scientific discovery and innovation through cancer research
Leaders in the Science of Cancer Care
At Montefiore Einstein Comprehensive Cancer Center, we’re committed to finding new and better cancer treatment options.
Our research breakthroughs continue to lead to game-changing cancer treatment practices and give patients a chance to join upcoming clinical trials, which may offer potentially successful treatment options. We’ve received accreditation from the NCI for the past 50 years in a row. Our facility is one of only 71 NCI-designated centers across the United States-and the only one located between Manhattan and New Haven. We made that expansion from Manhattan to Westchester to provide convenient access to cancer patients across the region.
State-of-the-Art Technology
At Montefiore Einstein Comprehensive Cancer Center, we are proud to provide patients with the newest technology available and offer the latest surgical and therapeutic techniques. Our goal is to utilize the least invasive solutions for your cancer care.
That is why we offer the latest in image-guided, immuno-, cellular and targeted therapies, to name just a few.
Some of our other molecular imaging technology includes the latest three-dimensional systems for bioluminescence imaging (BLI), fluorescence molecular imaging (FMI), positron emission tomography (PET) and single-photon emission computed tomography (SPECT).
Committed to Moving Faster Than Cancer
Cancer Center Highlights Report
Our Highlights Report documents our remarkable innovations in research, treatment and care.
-
$82M
in cancer relevant funding, of which $33 million is dedicated to philanthropy
-
1000+
patients enrolled in clinical research studies
-
400
papers published annually in high impact peer-reviewed journals
-
200+
types of cancer treated
Meet Your Cancer Care Team
Montefiore Einstein Comprehensive Cancer Center is home to 14 teams of award-winning, multidisciplinary experts who will develop a highly personalized treatment plan specific to your particular type of cancer, including those considered rare.
Events at Montefiore Einstein Comprehensive Cancer Center
Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2
-
Conditions
Breast Cancer
A Study Evaluating the Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients with Surgically Resectable Hepatocellular Carcinoma
-
Conditions
Hepatocellular Carcinoma
A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
-
Conditions
Non-Small Cell Lung Cancer
Study of IMPT-314 in R/R Aggressive B-Cell NHL
-
Conditions
elapsed/Refractory Non-Hodgkin’s Lymphoma
Phase 1/2 Study of PRO1160 in Patients with Metastatic Renal Cell Carcinoma (RCC), Metastatic or Relapsed Nasopharyngeal Carcinoma (NPC), or Advanced (Stage III or IV) Non-Hodgkins Lymphoma (NHL)
-
Conditions
Stage IV Renal Cell (kidney), Stage IV Nasopharyngeal, Stage III or IV Non-Hodgkins Lymphoma
A Randomized, Open-Label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians' Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease after Surgery and Neoadjuvant Therapy
-
Conditions
Triple Negative Breast Cancer
A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
-
Conditions
Non-Small Cell Lung Cancer
Study of BLU-222 in Advanced Solid Tumors
-
Conditions
Breast Cancer, Endometrial Cancer, Gastric Cancer, Ovarian Cancer
